Validation of PHPQoL, a Disease-Specific Quality-of-Life Questionnaire for Patients With Primary Hyperparathyroidism.

CONTEXT: Health-related quality of life (HRQoL) is impaired in primary hyperparathyroidism (PHPT) but instruments to specifically assess this are scarce. OBJECTIVE: Validate the new disease-specific Primary Hyperparathyroidism Quality of Life (PHPQoL) questionnaire in usual clinical practice. DESIGN: Observational, prospective, and multicenter. SETTING: Public hospital ambulatory care. PATIENTS: Patients with PHPT of both sexes, aged more than or equal to 18 years either initiated treatment for PHPT (group A) or had stable PHPT, not requiring therapy (group B). Patients in group A had at least one surgical criterion according to the 2009 Third International Workshop on Management of Asymptomatic PHPT. INTERVENTION: Sociodemographic, clinical, and HRQoL data (PHPQol, Short Form-36, Psychological Well-Being Index, and patients' self-perceived health status) were collected. Group A underwent 4 evaluations (baseline, 3 ± 1, 6 ± 1, and 12 ± 2 months after a therapeutic intervention) and group B 2, at baseline and 1 month later to assess test-retest reliability. RESULTS: A total of 182 patients were included (104 group A, 78 group B) with a mean age (SD) of 61.4 (12.1) years; 79.7% were women. Group A increased PHPQoL score (SD) (better HRQoL) (52 ± 23 at baseline; 62 ± 24 at 12 months; P < .001). At baseline, symptomatic patients had a lower PHPQoL score (worse) than asymptomatic ones (51 ± 21 vs 68 ± 21; P < .001). Correlations were seen between PHPQoL and Short Form-36, Psychological Well-Being Index, and self-perceived health status (P < .001). PHPQoL had good internal consistency (Cronbach's α = 0.80), test-retest reliability (group B, intraclass correlation coefficient > 0.80), and sensitivity to detect HQRoL changes over time. CONCLUSIONS: PHPQoL is a valid HRQoL measure to assess the impact of PHPT on health perception in clinical practice.

Impacto en la calidad de vida relacionada con la salud de pacientes con psoriasis activa y estable. Estudio PSO-LIFE / Impact of Active and Stable Psoriasis on Health-Related Quality of Life: The PSO-LIFE Study

Introducción y objetivos: El objetivo del estudio fue valorar el impacto de la psoriasis en la calidad de vida relacionada con la salud (CVRS) mediante diferentes cuestionarios de evaluación. Pacientes y métodos: Estudio observacional prospectivo en pacientes con psoriasis en placas de más de 6 meses de evolución, estratificándose en psoriasis activa (PsoA) y psoriasis estable (PsoE). Se realizó visita basal a los 7 días y al final (12 semanas). En cada una se recogieron características sociodemográficas y clínicas y cuestionarios de CVRS: Dermatology Life Quality Index (DLQI), Psoriasis Disability Index (PDI) y cuestionario de calidad de vida en psoriasis (PSO-LIFE). Resultados: Se evaluaron 304 pacientes: 182 con PsoA y 122 con PsoE. La edad media (DE) fue 45,3 (14,5) años y el 56,3% eran hombres. La puntuación media (DE) basal del PASI en PsoA fue 17,0 (7,4) y en PsoE fue 5,6 (5,3), disminuyendo durante el estudio (p < 0,01). La puntuación media (DE) del cuestionario PSO-LIFE aumentó de 57,4 (20,4) a 72,2 (19,6) en PsoA y de 76,4 (20,6) a 82,3 (18,3) en PsoE (p < 0,01 ambos).Las diferencias de las puntuaciones medias estandarizadas entre los 2 grupos fueron: 0,79 para el DLQI, 0,62 para el PDI y 0,85 para el PSO-LIFE. Los pacientes con lesiones en las zonas visibles tuvieron una mayor afectación según el cuestionario PSO-LIFE que los pacientes con afectación en zonas no tan visibles (p < 0,01).Los cambios en la puntuación del PSO-LIFE y los cambios en el PASI mostraron una correlación moderada (r = -0,4) y estadísticamente significativa. Conclusiones: Los pacientes con PsoA presentan una mayor afectación de la CVRS. El cuestionario PSO-LIFE mostró una mayor tendencia para discriminar entre ambos grupos de pacientes (PsoA y PsoE) que el DLQI y PDI. La localización de las lesiones y la gravedad, según el PASI, se correlacionaron de forma significativa con las puntuaciones del cuestionario PSO-LIFE (AU)

Introduction and objectives: The aim of this study was to assess the impact of psoriasis on health-related quality of life (HRQOL) using different questionnaires. Patients and methods: Prospective observational study of patients with plaque psoriasis of at least 6 months’ duration stratified by active and stable disease. The patients were evaluated at baseline, 7 days, and 12 weeks. At the 3 visits, the investigators recorded sociodemographic and clinical data and the patients completed the following HRQOL questionnaires: the Dermatology Life Quality Index (DLQI), the Psoriasis Disability Index (PDI), and psoriasis quality of life questionnaire (PSO-LIFE). Results: In total, 304 patients (182 with active psoriasis and 122 with stable psoriasis) were evaluated. The mean (SD) age was 45.3 (14.5) years, and 56.3% of the group were men. At baseline, the mean (SD) psoriasis and area severity index (PASI) score was 17.0 (7.4) in patients with active disease and 5.6 (5.3) in those with stable disease; a reduction was seen in PASI scores during the evaluation period (P < .01). The mean (SD) score on the PSO-LIFE questionnaire increased significantly from 57.4 (20.4) to 72.2 (19.6) in patients with active psoriasis and from 76.4 (20.6) to 82.3 (18.3) in those with stable disease (P < 0 .01 in both groups).The difference in standardized mean scores between the 2 groups was 0.79 for the DLQI, 0.62 for the PDI, and 0.85 for the PSO-LIFE questionnaire. The impact of psoriasis on HRQOL as assessed by the PSO-LIFE questionnaire was greater in patients with lesions in visible areas than in those with less visible lesions (P < 0.01). Changes in PSO-LIFE and PASI scores were moderately and significantly correlated (r = –0.4). Conclusions: The impact of psoriasis on HRQOL is higher in patients with active disease. The PSO-LIFE questionnaire showed a greater tendency to discriminate between active and stable psoriasis than either the DLQI or the PDI. PSO-LIFE scores correlated significantly with lesion site and disease severity as measured by PASI (AU)

Impact of active and stable psoriasis on health-related quality of life: the PSO-LIFE study.

INTRODUCTION AND OBJECTIVES: The aim of this study was to assess the impact of psoriasis on health-related quality of life (HRQOL) using different questionnaires. PATIENTS AND METHODS: Prospective observational study of patients with plaque psoriasis of at least 6 months' duration stratified by active and stable disease. The patients were evaluated at baseline, 7 days, and 12 weeks. At the 3 visits, the investigators recorded sociodemographic and clinical data and the patients completed the following HRQOL questionnaires: the Dermatology Life Quality Index (DLQI), the Psoriasis Disability Index (PDI), and psoriasis quality of life questionnaire (PSO-LIFE). RESULTS: In total, 304 patients (182 with active psoriasis and 122 with stable psoriasis) were evaluated. The mean (SD) age was 45.3 (14.5) years, and 56.3% of the group were men. At baseline, the mean (SD) psoriasis and area severity index (PASI) score was 17.0 (7.4) in patients with active disease and 5.6 (5.3) in those with stable disease; a reduction was seen in PASI scores during the evaluation period (P<.01). The mean (SD) score on the PSO-LIFE questionnaire increased significantly from 57.4 (20.4) to 72.2 (19.6) in patients with active psoriasis and from 76.4 (20.6) to 82.3 (18.3) in those with stable disease (P<0.01 in both groups). The difference in standardized mean scores between the 2 groups was 0.79 for the DLQI, 0.62 for the PDI, and 0.85 for the PSO-LIFE questionnaire. The impact of psoriasis on HRQOL as assessed by the PSO-LIFE questionnaire was greater in patients with lesions in visible areas than in those with less visible lesions (P<.01). Changes in PSO-LIFE and PASI scores were moderately and significantly correlated (r=-0.4). CONCLUSIONS: The impact of psoriasis on HRQOL is higher in patients with active disease. The PSO-LIFE questionnaire showed a greater tendency to discriminate between active and stable psoriasis than either the DLQI or the PDI. PSO-LIFE scores correlated significantly with lesion site and disease severity as measured by PASI.

Las preocupaciones en salud de las mujeres con osteoporosis; su satisfacción y adherencia / Health concerns of women with Osteoporosis; treatment

Introducción. El objetivo de este estudio ha sido conocer las preocupaciones en salud, la satisfacción con el tratamiento y la adherencia al mismo, en pacientes postmenopáusicas con osteoporosis. Pacientes y métodos. Se realizó un estudio epidemiológico multicéntrico en mujeres postmenopáusicas con osteoporosis mayores de 50 años y que iniciaban tratamiento con raloxifeno en 126 centros de Atención Primaria de España. Se evaluaron preocupaciones en salud al inicio del estudio, y satisfacción y adherencia terapéutica a los 3 y 12 meses. Resultados. Participaron 745 mujeres. En la visita basal el 58% se mostraron «bastante» o «muy» preocupadas por su salud en ese momento. La enfermedad que más preocupaba fue el cáncer (84,6%) y los problemas de salud que causaban más preocupación fueron perder memoria y/o lucidez (60%) y quedarse paralíticas (59%). El porcentaje de pacientes bastante-muy satisfechas con raloxifeno se mantuvo constante a lo largo del estudio (83%). La adherencia al tratamiento fue significativamente más alta en las pacientes con mayor satisfacción (p < 0,05). Conclusiones. La mitad de pacientes postmenopáusicas con osteoporosis refieren estar preocupadas por su salud actual. La satisfacción con el tratamiento con raloxifeno es alta y se mantiene estable a lo largo del estudio. Las pacientes satisfechas con el tratamiento muestran mayor adherencia terapéutica

Introduction. The aim of this study was to determine health concerns, treatment satisfaction and therapeutic adherence in post menopausal patients with osteoporosis. Patients and methods. An epidemiological, multicentre study was realized in women older than 50 years old with osteoporosis who had initiated treatment with raloxophine, in 126 Primary Care Centers in Spain. Health concerns were assessed at the beginning of the study and satisfaction and therapeutic adherence were both assessed at 3 and 12 months. Results. 745 women participated in the study. At baseline visit 58% were assessed as being moderately or highly concerned about their current health state. Prevalent among concerns over prospective diseases was that over cancer (84.6%), and among concerns over prospective health problems were those over memory loss and/or lucidity (60%) and paralysis (59%). The percentage of patients moderately ­ highly satisfied with raloxophine remained constant throughout all study (83%). Therapeutic adherence was significantly higher in patients showing higher satisfaction (p<0.05). Conclusions. Half of post menopausal patients with osteoporosis show concern over their current health state. Treatment satisfaction was high and remained stable throughout the study. Women satisfied with treatment show a higher therapeutic adherence